- Prof. Dario Marchetti
Division of Molecular Medicine, Department of Internal Medicine, The University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Website | E-mail
Special Issue Introduction
Brain metastasis represents a significant clinical and biological challenge with highly devastating and lethal consequences. An estimated 20% of all cancer patients will develop brain metastasis; however, this estimate is likely defective since autopsy studies have suggested a higher incidence (approximately 40%) of intracranial metastasis in patients with cancer. This special issue focuses on melanoma brain metastasis (MBM) which is diagnosed clinically in up to 60% of metastatic melanoma patients, and in up to 80% of patients at autopsy, and is a frequent initial site of disease progression. Notably, the overall patient survival of 2-5 years remains dismal at 8.1% and 2.4%, respectively, with a median overall survival of only 4 months from diagnosis. To date, MBM therapies include neurological resection of MBM lesions, stereotactic radiosurgery, whole brain radiotherapy for widespread disease, targeted therapy, and immunotherapy. While the latter has shown some significant activity, it is often less than what is observed for patients with only extracranial metastases. Furthermore, standard treatments result in high neurotoxicity, exacerbated by the fact that chemotherapeutic approaches are difficult to achieve dose success in the brain/central nervous system (CNS) due to the presence of the blood-brain barrier (BBB).
The objective of this special issue is to publish the latest advances in MBM basic and translational research, and clinical implementation combating MBM. Contributions outlining discoveries in MBM biological and clinical settings, including biological, technical, pre-clinical models, and clinical advances are welcome.
Submission Deadline30 Jun 2021